Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CCR6 | P51684 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | PTPRF | P10586 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30612232 | 0.86 | PTPRC (0.50) | MAPTGAASIRT2SIRT1PTPRC | |
| SCHEMBL7816235 | 0.86 | PTPRC (0.50) | MAPTGAASIRT2SIRT1PTPRC | |
| SCHEMBL27910874 | 0.82 | SIRT2 (0.41) | MAPTGAAALDH1A1SIRT2SIRT1 | |
| SCHEMBL856333 | 0.75 | TLR9 (0.52) | MAPTSIRT2SIRT1MEN1KMT2A | |
| SCHEMBL29671041 | 0.75 | POLB (0.54) | MAPTGAAALDH1A1CCR6NPSR1 | |
| SCHEMBL9156042 | 0.75 | POLB (0.54) | MAPTGAAALDH1A1CCR6NPSR1 | |
| SCHEMBL3254214 | 0.72 | PTPRC (0.45) | ALDH1A1SIRT2SIRT1PTPRCPTPRF | |
| SCHEMBL303331 | 0.71 | ALDH1A1 (0.51) | MAPTGAAALDH1A1CCR6NPSR1 | |
| SCHEMBL1473515 | 0.71 | MGLL (0.53) | MAPTGAAALDH1A1CCR6NPSR1 | |
| SCHEMBL1471696 | 0.71 | MGLL (0.53) | MAPTGAAALDH1A1CCR6NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090304663-A1 | USE OF GSK-3 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | IMPERIAL INNOVATIONS LIMITED (GB) | 2009-12-10 | — | — | US | claimed |
| EP-1786448-A1 | USE OF GSK-3 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | Imperial Innovations Limited (GB) | 2007-05-23 | — | — | EP | claimed |
| WO-2006018633-A1 | USE OF GSK-3 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | IMPERIAL INNOVATIONS LIMITED (GB) | 2006-02-23 | — | — | WO | claimed |
| US-20050075276-A1 | Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses | RUDD CHRISTOPHER (US) | 2005-04-07 | — | — | US | claimed |
| EP-2125683-B1 | 3-BENZOFURANYL-4-INDOLYL-MALEIMIDES AS POTENT GSK-3 INHIBITORS FOR NEURODEGENERATIVE DISORDERS | UNIV ILLINOIS (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8207216-B2 | Benzofuran-3-yl(indol-3-yl) maleimides as potent GSK3 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-06-26 | — | — | US | disclosed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20100105745-A1 | Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100004308-A1 | Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS | 2010-01-07 | — | — | US | disclosed |
| US-20090304663-A1 | USE OF GSK-3 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | IMPERIAL INNOVATIONS LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-7476676-B2 | Methods for increasing bone formation using inhibitors of glycogen synthase kinase-3β | ROCHE PALO ALTO LLC (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1465610-B1 | USE OF A GSK-3BETA INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INCREASING BONE FORMATION | HOFFMANN LA ROCHE (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-6479490-B2 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-6479490-B2 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| WO-2002010158-A3 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | HOFFMANN LA ROCHE (CH) | 2002-05-16 | — | — | WO | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
| WO-2002010158-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
| WO-2002010158-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004308-A1 | Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors | GSK3B, GSK3A, GSKIP | MAPT 22/4885GAA 1270/4885ALDH1A1 2460/4885 |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | MAPT 851/4885GAA 447/4885ALDH1A1 2363/4885 |
| US-20100105745-A1 | Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta | GSK3B, GSK3A, GSKIP | MAPT 3986/4885GAA 538/4885ALDH1A1 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.